Increased mucosal transmission but not enhanced pathogenicity of the CCR5-tropic, simian AIDS-inducing simian/human immunodeficiency virus SHIV(SF162P3) maps to envelope gp120 - PubMed (original) (raw)
Increased mucosal transmission but not enhanced pathogenicity of the CCR5-tropic, simian AIDS-inducing simian/human immunodeficiency virus SHIV(SF162P3) maps to envelope gp120
Mayla Hsu et al. J Virol. 2003 Jan.
Abstract
Through rapid serial transfer in vivo, the chimeric CCR5-tropic simian/human immunodeficiency virus SHIV(SF162) evolved from a virus that is nonpathogenic and poorly transmissible across the vaginal mucosa to a variant that still maintains CCR5 usage but which is now pathogenic and establishes intravaginal infection efficiently. To determine whether envelope glycoprotein gp120 is responsible for increased pathogenesis and transmissibility of the variant SHIV(SF162P3), we cloned and sequenced the dominant envelope gene (encoding P3 gp120) and characterized its functions in vitro. Chimeric SHIV(SF162) virus expressing P3 gp120 of the pathogenic variant, designated SHIV(SF162PC), was also constructed and assessed for its pathogenicity and mucosal transmissibility in vivo. We found that, compared to wild-type SHIV(SF162) gp120, P3 gp120 conferred in vitro neutralization resistance and increased entry efficiency of the virus but was compromised in its fusion-inducing capacity. In vivo, SHIV(SF162PC) infected two of two and two of three rhesus macaques by the intravenous and intravaginal routes, respectively. Nevertheless, although peak viremia reached 10(6) to 10(7) RNA copies per ml of plasma in some infected animals and was associated with depletion of gut-associated CD4(+) lymphocytes, none of the animals maintained a viral set point that would be predictive of progression to disease. Together, the data from this study suggest a lack of correlation between entry efficiency and cytopathic properties of envelope glycoproteins with viral pathogenicity. Furthermore, whereas env gp120 contains the determinant for enhanced mucosal transmissibility of SHIV(SF162P3), the determinant(s) of its increased virulence may require additional sequence changes in env gp41 and/or maps to other viral genes.
Figures
FIG. 1.
Amino acid sequence alignment of V1-V5 gp120 of SF162 and serially passaged clone P3. Dashes indicate amino acid identity. Amino acid changes generating new potential sites of N-linked glycosylation are boxed.
FIG. 2.
Neutralization of luciferase reporter viruses. (A) Neutralization by MAbs against the CD4 binding site (CD4bs), CD4 induced site (CD4i), and the V3 loop (anti-V3 loop). (B) Neutralization by sera isolated from a macaque infected with SHIVSF162 (serum 26419-32) and SHIVSF162P3 (serum 353-66N). Percent neutralization was determined by luciferase expression by viruses infected in the presence relative to the absence of antibodies. Three independent assays were carried out and representative neutralization curves are shown.
FIG. 3.
Relative entry of luciferase reporter viruses expressing SF162 gp120 or P3 gp120. (A) Entry of HOS.CD4.CCR5 cells. (B) Entry of CEMx174 5.25 M7 cells. Data for relative entry of HOS.CD4.CCR5 cells are the means and standard errors of six independent experiments, while those for CEMx174 5.25 M7 cells are the averages of two independent experiments.
FIG. 4.
Fusogenic capacity and susceptibility to T-20. (A) Fusion of SF162 and P3 gp120-expressing 293T cells with CEMx174 5.25 M7 cells. Results shown are the means and standard errors from three independent experiments. (B) Inhibition of luciferase reporter virus fusion with HOS.CD4.CCR5 cells by T-20. Viruses and T-20 were incubated for 1 h at 37°C before addition to cells, and inhibition relative to viruses in the absence of drug was calculated. The means and standard errors from three independent experiments are shown.
FIG. 5.
i.v. and IVAG infection of macaques. (A) i.v. infection of rhesus macaques with SHIVSF162PC. (B) IVAG infection of rhesus macaques with SHIVSF162PC. Filled symbols indicate viral loads expressed as RNA copies per milliliter, while empty symbols depict CD4/CD8 cell ratios. (C) Percentages of CD4+ lymphocytes from PBMCs, colonic lymph node mononuclear cells (LNMC), and lamina propria (LPL) during acute infection. The percentage of CD4+ lymphocytes in the intestinal tract of uninfected macaques has been shown to be in the range of 34 to 57% (75).
Similar articles
- V3 loop-determined coreceptor preference dictates the dynamics of CD4+-T-cell loss in simian-human immunodeficiency virus-infected macaques.
Ho SH, Shek L, Gettie A, Blanchard J, Cheng-Mayer C. Ho SH, et al. J Virol. 2005 Oct;79(19):12296-303. doi: 10.1128/JVI.79.19.12296-12303.2005. J Virol. 2005. PMID: 16160156 Free PMC article. - Expansion of quasispecies diversity but no evidence for adaptive evolution of SHIV during rapid serial transfers among seronegative macaques.
Balfe P, Shapiro S, Hsu M, Buckner C, Harouse JM, Cheng-Mayer C. Balfe P, et al. Virology. 2004 Jan 5;318(1):267-79. doi: 10.1016/j.virol.2003.09.022. Virology. 2004. PMID: 14972553 - Simian-human immunodeficiency virus containing a human immunodeficiency virus type 1 subtype-E envelope gene: persistent infection, CD4(+) T-cell depletion, and mucosal membrane transmission in macaques.
Himathongkham S, Halpin NS, Li J, Stout MW, Miller CJ, Luciw PA. Himathongkham S, et al. J Virol. 2000 Sep;74(17):7851-60. doi: 10.1128/jvi.74.17.7851-7860.2000. J Virol. 2000. PMID: 10933692 Free PMC article. - Understanding the basis of CD4(+) T-cell depletion in macaques infected by a simian-human immunodeficiency virus.
Etemad-Moghadam B, Rhone D, Steenbeke T, Sun Y, Manola J, Gelman R, Fanton JW, Racz P, Tenner-Racz K, Axthelm MK, Letvin NL, Sodroski J. Etemad-Moghadam B, et al. Vaccine. 2002 May 6;20(15):1934-7. doi: 10.1016/s0264-410x(02)00072-5. Vaccine. 2002. PMID: 11983249 Review. - HIV-1 envelope, integrins and co-receptor use in mucosal transmission of HIV.
Cicala C, Arthos J, Fauci AS. Cicala C, et al. J Transl Med. 2011 Jan 27;9 Suppl 1(Suppl 1):S2. doi: 10.1186/1479-5876-9-S1-S2. J Transl Med. 2011. PMID: 21284901 Free PMC article. Review.
Cited by
- Replication competent HIV-guided CRISPR screen identifies antiviral factors including targets of the accessory protein Nef.
Prelli Bozzo C, Laliberté A, De Luna A, Pastorio C, Regensburger K, Krebs S, Graf A, Blum H, Volcic M, Sparrer KMJ, Kirchhoff F. Prelli Bozzo C, et al. Nat Commun. 2024 May 7;15(1):3813. doi: 10.1038/s41467-024-48228-x. Nat Commun. 2024. PMID: 38714682 Free PMC article. - Rational design and in vivo selection of SHIVs encoding transmitted/founder subtype C HIV-1 envelopes.
O'Brien SP, Swanstrom AE, Pegu A, Ko SY, Immonen TT, Del Prete GQ, Fennessey CM, Gorman J, Foulds KE, Schmidt SD, Doria-Rose N, Williamson C, Hatziioannou T, Bieniasz PD, Li H, Shaw GM, Mascola JR, Koup RA, Kwong PD, Lifson JD, Roederer M, Keele BF. O'Brien SP, et al. PLoS Pathog. 2019 Apr 3;15(4):e1007632. doi: 10.1371/journal.ppat.1007632. eCollection 2019 Apr. PLoS Pathog. 2019. PMID: 30943274 Free PMC article. - A Degraded Fragment of HIV-1 Gp120 in Rat Hepatocytes Forms Fibrils and Enhances HIV-1 Infection.
Chen J, Ren R, Yu F, Wang C, Zhang X, Li W, Tan S, Jiang S, Liu S, Li L. Chen J, et al. Biophys J. 2017 Oct 3;113(7):1425-1439. doi: 10.1016/j.bpj.2017.08.005. Biophys J. 2017. PMID: 28978437 Free PMC article. - A single gp120 residue can affect HIV-1 tropism in macaques.
Del Prete GQ, Keele BF, Fode J, Thummar K, Swanstrom AE, Rodriguez A, Raymond A, Estes JD, LaBranche CC, Montefiori DC, KewalRamani VN, Lifson JD, Bieniasz PD, Hatziioannou T. Del Prete GQ, et al. PLoS Pathog. 2017 Sep 25;13(9):e1006572. doi: 10.1371/journal.ppat.1006572. eCollection 2017 Sep. PLoS Pathog. 2017. PMID: 28945790 Free PMC article. - Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies.
Fuchs SP, Desrosiers RC. Fuchs SP, et al. Mol Ther Methods Clin Dev. 2016 Nov 16;3:16068. doi: 10.1038/mtm.2016.68. eCollection 2016. Mol Ther Methods Clin Dev. 2016. PMID: 28197421 Free PMC article. Review.
References
- Albert, J., B. Abrahamsson, K. Nagy, E. Aurelius, H. Gaines, G. Nystrom, and E. M. Fenyo. 1990. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 4:107-112. - PubMed
- Arendrup, M., C. Nielsen, J. E. Hansen, C. Pedersen, L. Mathiesen, and J. O. Nielsen. 1992. Autologous HIV-1 neutralizing antibodies: emergence of neutralization-resistant escape virus and subsequent development of escape virus neutralizing antibodies. J. Acquir. Immune Defic. Syndr. 5:303-307. - PubMed
- Baba, T. W., V. Liska, R. Hofmann-Lehmann, J. Vlasak, W. Xu, S. Ayehunie, L. A. Cavacini, M. R. Posner, H. Katinger, G. Stiegler, B. J. Bernacky, T. A. Rizvi, R. Schmidt, L. R. Hill, M. E. Keeling, Y. Lu, J. E. Wright, T. C. Chou, and R. M. Ruprecht. 2000. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6:200-206. - PubMed
- Berger, E. A. 1997. HIV entry and tropism: the chemokine receptor connection. AIDS 11:S3-S16. - PubMed
- Berkowitz, R. D., A. B. van't Wout, N. A. Kootstra, M. E. Moreno, V. D. Linquist-Stepps, C. Bare, C. A. Stoddart, H. Schuitemaker, and J. M. McCune. 1999. R5 strains of human immunodeficiency virus type 1 from rapid progressors lacking X4 strains do not possess X4-type pathogenicity in human thymus. J. Virol. 73:7817-7822. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- AI46980/AI/NIAID NIH HHS/United States
- R37 AI041945/AI/NIAID NIH HHS/United States
- P51 RR000164/RR/NCRR NIH HHS/United States
- CA72822/CA/NCI NIH HHS/United States
- R01 CA072822/CA/NCI NIH HHS/United States
- R01 AI041945/AI/NIAID NIH HHS/United States
- R01 AI046980/AI/NIAID NIH HHS/United States
- AI41945/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Research Materials